Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025LiversOpen Access

Synthalin, Buformin, Phenformin, and Metformin: A Century of Intestinal “Glucose Excretion” as Oral Antidiabetic Strategy in Overweight/Obese Patients

View Full Paper
Ask AI
Bookmark
Share

Authors

GRG Ramadori

Discussion

Loading...

Member takes

Overview

Historical overview shows metformin’s efficacy in managing type 2 diabetes in overweight patients, highlighting its mechanisms and potential side effects.

Key Points

  • Metformin is the most widely used oral drug for managing type 2 diabetes globally, with unique mechanisms for glucose absorption.
  • It reduces glucose absorption and enhances intestinal glucose excretion, improving metabolic control in overweight type 2 diabetic patients.
  • All biguanides, including metformin, may lead to significant gastrointestinal side effects, which can limit patient adherence to therapy.
  • Chronic dehydration and vitamin B12 deficiency are long-term side effects associated with biguanide treatments like metformin.

Cite This Study

G Ramadori (2025) studied this question.

synapsesocial.com/papers/68c240deb210217d6479c9e6https://doi.org/10.3390/livers5030035
View Full Paper
Ask AI
Bookmark
Share